SGLT2 inhibitors: are they safe?

References

• Chamberlain JJ, Herman WH, Leal S, et al. Pharmacologic therapy for type 2 diabetes: synopsis of the 2017 American Diabetes Association Standards of Medical Care in Diabetes. Ann Intern Med. 2017;166:572–578.
   PubMed Web of Science ®Google Scholar
• Filippatos TD, Florentin M, Georgoula M, et al. Pharmacological management of diabetic dyslipidemia. Expert Rev Clin Pharmacol. 2017;10:187–200.
   PubMed Web of Science ®Google Scholar
• Agouridis AP, Rizos CV, Elisaf MS, et al. Does combination therapy with statins and fibrates prevent cardiovascular disease in diabetic patients with atherogenic mixed dyslipidemia? Rev Diabet Stud. 2013;10:171–190.
   PubMedGoogle Scholar
• Filippatos TD, Elisaf MS. Pitavastatin and carbohydrate metabolism: what is the evidence? Expert Rev Clin Pharmacol. 2016;9:955–960.
   PubMed Web of Science ®Google Scholar
• Filippatos TD, Elisaf MS. Fenofibrate plus simvastatin (fixed-dose combination) for the treatment of dyslipidaemia. Expert Opin Pharmacother. 2011;12:1945–1958.
   PubMed Web of Science ®Google Scholar
• Filippatos TD, Kei A, Rizos CV, et al. Effects of PCSK9 inhibitors on other than low-density lipoprotein cholesterol lipid variables. J Cardiovasc Pharmacol Ther. 2017; Epub ahead of print. DOI: 1074248417724868.
   PubMed Web of Science ®Google Scholar
• Filippatos TD, Filippas-Ntekouan S, Pappa E, et al. PCSK9 and carbohydrate metabolism: a double-edged sword. World J Diabetes. 2017;8:311–316.
   PubMed Web of Science ®Google Scholar
• Filippatos TD, Panagiotakos DB, Georgousopoulou EN, et al. Mediterranean diet and 10-year (2002–2012) incidence of diabetes and cardiovascular disease in participants with prediabetes: the ATTICA study. Rev Diabet Stud. 2016;13:226–235.
   PubMedGoogle Scholar
• Filippatos TD, Klouras E, Barkas F, et al. Cholesteryl ester transfer protein inhibitors: challenges and perspectives. Expert Rev Cardiovasc Ther. 2016;14:953–962.
   PubMed Web of Science ®Google Scholar
• Pfeffer MA, Claggett B, Diaz R, et al. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med. 2015;373:2247–2257.
   PubMed Web of Science ®Google Scholar
• Green JB, Bethel MA, Armstrong PW, et al. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2015;373:232–242.
   PubMed Web of Science ®Google Scholar
• White WB, Cannon CP, Heller SR, et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med. 2013;369:1327–1335.
   PubMed Web of Science ®Google Scholar
• Scirica BM, Bhatt DL, Braunwald E, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013;369:1317–1326.
   PubMed Web of Science ®Google Scholar
• Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375:311–322.
   PubMed Web of Science ®Google Scholar
• Filippatos TD, Panagiotopoulou TV, Elisaf MS. Adverse effects of GLP-1 receptor agonists. Rev Diabet Stud. 2014;11:202–230.
   PubMedGoogle Scholar
• Filippatos TD, Athyros VG, Elisaf MS, et al. The pharmacokinetic considerations and adverse effects of DPP-4 inhibitors. Expert Opin Drug Metab Toxicol. 2014;10:787–812.
   PubMed Web of Science ®Google Scholar
• Filippatos TD, Elisaf MS. Effects of glucagon-like peptide-1 receptor agonists on renal function. World J Diabetes. 2013;4:190–201.
   PubMedGoogle Scholar
• Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375:1834–1844.
   PubMed Web of Science ®Google Scholar
• Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373:2117–2128.
   PubMed Web of Science ®Google Scholar
• Wanner C, Inzucchi SE, Lachin JM, et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med. 2016;375:323–334.
   PubMed Web of Science ®Google Scholar
• Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017.
   Web of Science ®Google Scholar
• Wu JH, Foote C, Blomster J, et al. Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes: a systematic review and meta-analysis. Lancet Diabetes Endocrinol. 2016;4:411–419.
   PubMed Web of Science ®Google Scholar
• Tsimihodimos V, Filippatos TD, Filippas-Ntekouan S, et al. Renoprotective effects of SGLT2 inhibitors: beyond glucose reabsorption inhibition. Curr Vasc Pharmacol. 2017;15:96–102.
   PubMed Web of Science ®Google Scholar
• Tsimihodimos V, Filippatos TD, Elisaf MS. Effects of sodium-glucose co-transporter 2 inhibitors on metabolism: unanswered questions and controversies. Expert Opin Drug Metab Toxicol. 2017;13:399–408.
   PubMed Web of Science ®Google Scholar
• Filippatos TD, Tsimihodimos V, Elisaf MS. Mechanisms of blood pressure reduction with sodium-glucose co-transporter 2 (SGLT2) inhibitors. Expert Opin Pharmacother. 2016;17:1581–1583.
   PubMed Web of Science ®Google Scholar
• Filippatos TD, Liberopoulos EN, Elisaf MS. Dapagliflozin in patients with type 2 diabetes mellitus. Ther Adv Endocrinol Metab. 2015;6:29–41.
   PubMed Web of Science ®Google Scholar
• Giovannucci E, Harlan DM, Archer MC, et al. Diabetes and cancer: a consensus report. Diabetes Care. 2010;33:1674–1685.
   PubMed Web of Science ®Google Scholar
• Mayor S. Cancer risk is higher in years before and shortly after type 2 diabetes diagnosis, study shows. BMJ. 2016;354:i3832.
   PubMed Web of Science ®Google Scholar
• Lutz SZ, Staiger H, Fritsche A, et al. Antihyperglycaemic therapies and cancer risk. Diab Vasc Dis Res. 2014;11:371–389.
   PubMed Web of Science ®Google Scholar
• Rizos CV, Elisaf MS. Metformin and cancer. Eur J Pharmacol. 2013;705:96–108.
   PubMed Web of Science ®Google Scholar
• Tuccori M, Filion KB, Yin H, et al. Pioglitazone use and risk of bladder cancer: population based cohort study. BMJ. 2016;352:i1541.
   PubMed Web of Science ®Google Scholar
• Rizos CV, Kei A, Elisaf MS. The current role of thiazolidinediones in diabetes management. Arch Toxicol. 2016;90:1861–1881.
   PubMed Web of Science ®Google Scholar
• U.S. Food and Drug Administration. FDA briefing document, NDA 202293 dapagliflozin tablets, 5 and 10 mg. Advisory committee meeting. 2011. http://www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/drugs/endocrinologicandmetabolicdrugsadvisorycommittee/ucm262994.pdf
   Google Scholar
• U.S. Food and Drug Administration. FDA background document, BMS-512148 NDA 202293 dapagliflozin. Proceedings of the endocrinologic & metabolic drug advisory committee meeting. 2013. http://www.fda.gov/downloads/drugs/endocrinologicandmetabolicdrugsadvisorycommittee/ucm378079.pdf
   Google Scholar
• Ptaszynska A, Cohen SM, Messing EM, et al. Assessing bladder cancer risk in type 2 diabetes clinical trials: the dapagliflozin drug development program as a ‘case study’. Diabetes Ther. 2015;6:357–375.
   PubMed Web of Science ®Google Scholar
• Reilly TP, Graziano MJ, Janovitz EB, et al. Carcinogenicity risk assessment supports the chronic safety of dapagliflozin, an inhibitor of sodium-glucose co-transporter 2, in the treatment of type 2 diabetes mellitus. Diabetes Ther. 2014;5:73–96.
   PubMed Web of Science ®Google Scholar
• Lin HW, Tseng CH. A review on the relationship between SGLT2 inhibitors and cancer. Int J Endocrinol. 2014;2014:719578.
   PubMed Web of Science ®Google Scholar
• Tang H, Dai Q, Shi W, et al. SGLT2 inhibitors and risk of cancer in type 2 diabetes: a systematic review and meta-analysis of randomised controlled trials. Diabetologia. 2017.
   Web of Science ®Google Scholar
• Scafoglio C, Hirayama BA, Kepe V, et al. Functional expression of sodium-glucose transporters in cancer. Proc Natl Acad Sci USA. 2015;112:E4111–9.
   PubMed Web of Science ®Google Scholar
• Cangoz S, Chang YY, Chempakaseril SJ, et al. The kidney as a new target for antidiabetic drugs: SGLT2 inhibitors. J Clin Pharm Ther. 2013;38:350–359.
   PubMed Web of Science ®Google Scholar
• Kitabchi AE, Umpierrez GE, Murphy MB, et al. Hyperglycemic crises in adult patients with diabetes: a consensus statement from the American Diabetes Association. Diabetes Care. 2006;29:2739–2748.
   PubMed Web of Science ®Google Scholar
• Wang ZH, Kihl-Selstam E, Eriksson JW. Ketoacidosis occurs in both type 1 and type 2 diabetes – a population-based study from Northern Sweden. Diabet Med. 2008;25:867–870.
   PubMed Web of Science ®Google Scholar
• Chiasson JL, Aris-Jilwan N, Belanger R, et al. Diagnosis and treatment of diabetic ketoacidosis and the hyperglycemic hyperosmolar state. CMAJ. 2003;168:859–866.
   PubMed Web of Science ®Google Scholar
• Turner J, Begum T, Smalligan RD. Canagliflozin-induced diabetic ketoacidosis: case report and review of the literature. J Investig Med High Impact Case Rep. 2016;4:2324709616663231.
   Google Scholar
• Clement M, Senior P. Euglycemic diabetic ketoacidosis with canagliflozin: not-so-sweet but avoidable complication of sodium-glucose cotransporter-2 inhibitor use. Can Fam Physician. 2016;62:725–728.
   PubMed Web of Science ®Google Scholar
• Taylor SI, Blau JE, Rother KI. SGLT2 inhibitors may predispose to ketoacidosis. J Clin Endocrinol Metab. 2015;100:2849–2852.
   PubMed Web of Science ®Google Scholar
• Abdul-Ghani MA, Norton L, DeFronzo RA. Renal sodium-glucose cotransporter inhibition in the management of type 2 diabetes mellitus. Am J Physiol Renal Physiol. 2015;309:F889–900.
   PubMed Web of Science ®Google Scholar
• Yanai H, Katsuyama H, Hamasaki H, et al. Sodium-glucose cotransporter 2 inhibitors: possible anti-atherosclerotic effects beyond glucose lowering. J Clin Med Res. 2016;8:10–14.
   PubMedGoogle Scholar
• Bonner C, Kerr-Conte J, Gmyr V, et al. Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion. Nat Med. 2015;21:512–517.
   PubMed Web of Science ®Google Scholar
• Merovci A, Solis-Herrera C, Daniele G, et al. Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production. J Clin Invest. 2014;124:509–514.
   PubMed Web of Science ®Google Scholar
• Ferrannini E, Muscelli E, Frascerra S, et al. Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. J Clin Invest. 2014;124:499–508.
   PubMed Web of Science ®Google Scholar
• Pieber TR, Famulla S, Eilbracht J, et al. Empagliflozin as adjunct to insulin in patients with type 1 diabetes: a 4-week, randomized, placebo-controlled trial (EASE-1). Diabetes Obes Metab. 2015;17:928–935.
   PubMed Web of Science ®Google Scholar
• Ferrannini E, Baldi S, Frascerra S, et al. Shift to fatty substrate utilization in response to sodium-glucose cotransporter 2 inhibition in subjects without diabetes and patients with type 2 diabetes. Diabetes. 2016;65:1190–1195.
   PubMed Web of Science ®Google Scholar
• Filippatos T, Tzavella E, Rizos C. Acid-base and electrolyte disorders associated with the use of antidiabetic drugs. Expert Opin Drug Saf. 2017:16:121-1132.
   PubMed Web of Science ®Google Scholar
• Fadini GP, Bonora BM, Avogaro A. SGLT2 inhibitors and diabetic ketoacidosis: data from the FDA Adverse Event Reporting System. Diabetologia. 2017;60:1385–1389.
   PubMed Web of Science ®Google Scholar
• Rosenstock J, Ferrannini E. Euglycemic diabetic ketoacidosis: a predictable, detectable, and preventable safety concern with SGLT2 inhibitors. Diabetes Care. 2015;38:1638–1642.
   PubMed Web of Science ®Google Scholar
• Goldenberg RM, Berard LD, Cheng AY, et al. SGLT2 inhibitor-associated diabetic ketoacidosis: clinical review and recommendations for prevention and diagnosis. Clin Ther. 2016;38:2654–64.e1.
   PubMed Web of Science ®Google Scholar
• Wang Y, Desai M, Ryan PB, et al. Incidence of diabetic ketoacidosis among patients with type 2 diabetes mellitus treated with SGLT2 inhibitors and other antihyperglycemic agents. Diabetes Res Clin Pract. 2017;128:83–90.
   PubMed Web of Science ®Google Scholar
• Tang H, Li D, Wang T, et al. Effect of sodium-glucose cotransporter 2 inhibitors on diabetic ketoacidosis among patients with type 2 diabetes: a meta-analysis of randomized controlled trials. Diabetes Care. 2016;39:e123–4.
   PubMed Web of Science ®Google Scholar
• Monami M, Nreu B, Zannoni S, et al. Effects of SGLT-2 inhibitors on diabetic ketoacidosis: a meta-analysis of randomised controlled trials. Diabetes Res Clin Pract. 2017;130:53–60.
   PubMed Web of Science ®Google Scholar
• Ferrannini E, Mark M, Mayoux E. CV protection in the EMPA-REG OUTCOME trial: a “thrifty substrate” hypothesis. Diabetes Care. 2016;39:1108–1114.
   PubMed Web of Science ®Google Scholar
• Mudaliar S, Alloju S, Henry RR. Can a shift in fuel energetics explain the beneficial cardiorenal outcomes in the EMPA-REG OUTCOME study? A unifying hypothesis. Diabetes Care. 2016;39:1115–1122.
   PubMed Web of Science ®Google Scholar
• Benfield T, Jensen JS, Nordestgaard BG. Influence of diabetes and hyperglycaemia on infectious disease hospitalisation and outcome. Diabetologia. 2007;50:549–554.
   PubMed Web of Science ®Google Scholar
• Geerlings SE, Meiland R, van Lith EC, et al. Adherence of type 1-fimbriated Escherichia coli to uroepithelial cells: more in diabetic women than in control subjects. Diabetes Care. 2002;25:1405–1409.
   PubMed Web of Science ®Google Scholar
• Geerlings SE, Brouwer EC, Gaastra W, et al. Effect of glucose and pH on uropathogenic and non-uropathogenic Escherichia coli: studies with urine from diabetic and non-diabetic individuals. J Med Microbiol. 1999;48:535–539.
   PubMed Web of Science ®Google Scholar
• Delamaire M, Maugendre D, Moreno M, et al. Impaired leucocyte functions in diabetic patients. Diabet Med. 1997;14:29–34.
   PubMed Web of Science ®Google Scholar
• Zhang X, Essmann M, Burt ET, et al. Estrogen effects on Candida albicans: a potential virulence-regulating mechanism. J Infect Dis. 2000;181:1441–1446.
   PubMed Web of Science ®Google Scholar
• Donders GG, Babula O, Bellen G, et al. Mannose-binding lectin gene polymorphism and resistance to therapy in women with recurrent vulvovaginal candidiasis. Bjog. 2008;115:1225–1231.
   PubMed Web of Science ®Google Scholar
• Achkar JM, Fries BC. Candida infections of the genitourinary tract. Clin Microbiol Rev. 2010;23:253–273.
   PubMed Web of Science ®Google Scholar
• Njomnang Soh P, Vidal F, Huyghe E, et al. Urinary and genital infections in patients with diabetes: how to diagnose and how to treat. Diabetes Metab. 2016;42:16–24.
   PubMed Web of Science ®Google Scholar
• Geerlings S, Fonseca V, Castro-Diaz D, et al. Genital and urinary tract infections in diabetes: impact of pharmacologically-induced glucosuria. Diabetes Res Clin Pract. 2014;103:373–381.
   PubMed Web of Science ®Google Scholar
• Goswami R, Dadhwal V, Tejaswi S, et al. Species-specific prevalence of vaginal candidiasis among patients with diabetes mellitus and its relation to their glycaemic status. J Infect. 2000;41:162–166.
   PubMed Web of Science ®Google Scholar
• Fidel PL, Vazquez JA, Sobel JD. Candida glabrata: review of epidemiology, pathogenesis, and clinical disease with comparison to C. albicans. Clinical Microbiology Reviews. 1999;12:80–96.
   PubMed Web of Science ®Google Scholar
• Jabbour SA, Hardy E, Sugg J, et al. Dapagliflozin is effective as add-on therapy to sitagliptin with or without metformin: a 24-week, multicenter, randomized, double-blind, placebo-controlled study. Diabetes Care. 2014;37:740–750.
   PubMed Web of Science ®Google Scholar
• Bode B, Stenlof K, Harris S, et al. Long-term efficacy and safety of canagliflozin over 104 weeks in patients aged 55-80 years with type 2 diabetes. Diabetes Obes Metab. 2015;17:294–303.
   PubMed Web of Science ®Google Scholar
• Haering HU, Merker L, Christiansen AV, et al. Empagliflozin as add-on to metformin plus sulphonylurea in patients with type 2 diabetes. Diabetes Res Clin Pract. 2015;110:82–90.
   PubMed Web of Science ®Google Scholar
• Yang Y, Chen S, Pan H, et al. Safety and efficiency of SGLT2 inhibitor combining with insulin in subjects with diabetes: systematic review and meta-analysis of randomized controlled trials. Medicine (Baltimore). 2017;96:e6944.
   PubMed Web of Science ®Google Scholar
• Kawalec P, Mikrut A, Lopuch S. The safety of dipeptidyl peptidase-4 (DPP-4) inhibitors or sodium-glucose cotransporter 2 (SGLT-2) inhibitors added to metformin background therapy in patients with type 2 diabetes mellitus: a systematic review and meta-analysis. Diabetes Metab Res Rev. 2014;30:269–283.
   PubMed Web of Science ®Google Scholar
• Vasilakou D, Karagiannis T, Athanasiadou E, et al. Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis. Ann Intern Med. 2013;159:262–274.
   PubMed Web of Science ®Google Scholar
• Liu J, Li L, Li S. Effects of SGLT2 inhibitors on UTIs and genital infections in type 2 diabetes mellitus: a systematic review and meta-analysis. Sci Rep. 2017;7:2824.
   PubMed Web of Science ®Google Scholar
• Zaccardi F, Webb DR, Htike ZZ, et al. Efficacy and safety of sodium-glucose co-transporter-2 inhibitors in type 2 diabetes mellitus: systematic review and network meta-analysis. Diabetes Obes Metab. 2016;18:783–794.
   PubMed Web of Science ®Google Scholar
• Li D, Wang T, Shen S, et al. Urinary tract and genital infections in patients with type 2 diabetes treated with sodium-glucose co-transporter 2 inhibitors: a meta-analysis of randomized controlled trials. Diabetes Obes Metab. 2017;19:348–355.
   PubMed Web of Science ®Google Scholar
• Thong KY, Yadagiri M, Barnes DJ, et al. Clinical risk factors predicting genital fungal infections with sodium-glucose cotransporter 2 inhibitor treatment: the ABCD nationwide dapagliflozin audit. Prim Care Diabetes. 2017; Epub ahead of print. DOI: 10.1016/j.pcd.2017.06.004
   PubMed Web of Science ®Google Scholar
• Kufel WD, Scrimenti A, Steele JM. A case of septic shock due to Serratia marcescens pyelonephritis and bacteremia in a patient receiving empagliflozin. J Pharm Pract. 2016.
   PubMedGoogle Scholar
• Hall V, Kwong J, Johnson D, et al. Caution advised with dapagliflozin in the setting of male urinary tract outlet obstruction. BMJ Case Rep. 2017;2017. DOI:10.1136/bcr-2017-219335
   PubMedGoogle Scholar
• Kohler S, Zeller C, Iliev H, et al. Safety and tolerability of empagliflozin in patients with type 2 diabetes: pooled analysis of phase I-III clinical trials. Adv Ther. 2017;34:1707–1726.
   PubMed Web of Science ®Google Scholar
• Monami M, Zannoni S, Nreu B, et al. Toe amputations with SGLT-2 inhibitors: data from randomized clinical trials. Acta Diabetol. 2017;54:411–413.
   PubMed Web of Science ®Google Scholar
• Fadini GP, Avogaro A. SGTL2 inhibitors and amputations in the US FDA Adverse Event Reporting System. Lancet Diabetes Endocrinol. 2017;5:680681.
   PubMed Web of Science ®Google Scholar
• Tang H, Zhang X, Zhang J, et al. Elevated serum magnesium associated with SGLT2 inhibitor use in type 2 diabetes patients: a meta-analysis of randomised controlled trials. Diabetologia. 2016;59:2546–2551.
   PubMed Web of Science ®Google Scholar
• Gilbert RE, Mende C, Vijapurkar U, et al. Effects of canagliflozin on serum magnesium in patients with type 2 diabetes mellitus: a post hoc analysis of randomized controlled trials. Diabetes Ther. 2017;8:451–458.
   PubMed Web of Science ®Google Scholar
• Filippatos TD, Tsimihodimos V, Liamis G, et al. SGLT2 inhibitors-induced electrolyte abnormalities: an analysis of the associated mechanisms. Diabetes Metab Syndr. 2017; Epub ahead of print. DOI: 10.1016/j.dsx.2017.08.03
   Google Scholar
• Merovci A, Mari A, Solis C, et al. Dapagliflozin lowers plasma glucose concentration and improves beta-cell function. J Clin Endocrinol Metab. 2015;100:1927–1932.
   PubMed Web of Science ®Google Scholar
• Takayanagi K, Shimizu T, Tayama Y, et al. Downregulation of transient receptor potential M6 channels as a cause of hypermagnesiuric hypomagnesemia in obese type 2 diabetic rats. Am J Physiol Renal Physiol. 2015;308:F1386–97.
   PubMed Web of Science ®Google Scholar
• Bankir L, Bouby N, Blondeau B, et al. Glucagon actions on the kidney revisited: possible role in potassium homeostasis. Am J Physiol Renal Physiol. 2016;311:F469–86.
   PubMed Web of Science ®Google Scholar
• Xu LH, Maalouf NM. Effect of acute hyperinsulinemia on magnesium homeostasis in humans. Diabetes Metab Res Rev. 2017;33:e2844.
   Web of Science ®Google Scholar
• Barnett AH, Mithal A, Manassie J, et al. Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol. 2014;2:369–384.
   PubMed Web of Science ®Google Scholar
• Kohan DE, Fioretto P, Tang W, et al. Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control. Kidney Int. 2014;85:962–971.
   PubMed Web of Science ®Google Scholar
• Yavin Y, Mansfield TA, Ptaszynska A, et al. Effect of the SGLT2 inhibitor dapagliflozin on potassium levels in patients with type 2 diabetes mellitus: a pooled analysis. Diabetes Ther. 2016;7:125–137.
   PubMed Web of Science ®Google Scholar
• Weir MR, Kline I, Xie J, et al. Effect of canagliflozin on serum electrolytes in patients with type 2 diabetes in relation to estimated glomerular filtration rate (eGFR). Curr Med Res Opin. 2014;30:1759–1768.
   PubMed Web of Science ®Google Scholar
• Kimura G. Importance of inhibiting sodium-glucose cotransporter and its compelling indication in type 2 diabetes: pathophysiological hypothesis. J Am Soc Hypertens. 2016;10:271–278.
   PubMed Web of Science ®Google Scholar
• Taylor SI, Blau JE, Rother KI. Possible adverse effects of SGLT2 inhibitors on bone. Lancet Diabetes Endocrinol. 2015;3:8–10.
   PubMed Web of Science ®Google Scholar
• Watts NB, Bilezikian JP, Usiskin K, et al. Effects of canagliflozin on fracture risk in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab. 2016;101:157–166.
   PubMed Web of Science ®Google Scholar
• Tang HL, Li DD, Zhang JJ, et al. Lack of evidence for a harmful effect of sodium-glucose co-transporter 2 (SGLT2) inhibitors on fracture risk among type 2 diabetes patients: a network and cumulative meta-analysis of randomized controlled trials. Diabetes Obes Metab. 2016;18:1199–1206.
   PubMed Web of Science ®Google Scholar
• Ruanpeng D, Ungprasert P, Sangtian J, et al. Sodium-glucose cotransporter 2 (SGLT2) inhibitors and fracture risk in patients with type 2 diabetes mellitus: a meta-analysis. Diabetes Metab Res Rev. 2017;33:e2903.
   PubMed Web of Science ®Google Scholar
• Bilezikian JP, Watts NB, Usiskin K, et al. Evaluation of bone mineral density and bone biomarkers in patients with type 2 diabetes treated with canagliflozin. J Clin Endocrinol Metab. 2016;101:44–51.
   PubMed Web of Science ®Google Scholar
• Ljunggren O, Bolinder J, Johansson L, et al. Dapagliflozin has no effect on markers of bone formation and resorption or bone mineral density in patients with inadequately controlled type 2 diabetes mellitus on metformin. Diabetes Obes Metab. 2012;14:990–999.
   PubMed Web of Science ®Google Scholar
• Inagaki N, Goda M, Yokota S, et al. Effects of baseline blood pressure and low-density lipoprotein cholesterol on safety and efficacy of canagliflozin in Japanese patients with type 2 diabetes mellitus. Adv Ther. 2015;32:1085–1103.
   PubMed Web of Science ®Google Scholar
• Liakos A, Karagiannis T, Athanasiadou E, et al. Efficacy and safety of empagliflozin for type 2 diabetes: a systematic review and meta-analysis. Diabetes Obes Metab. 2014;16:984–993.
   PubMed Web of Science ®Google Scholar
• Musso G, Gambino R, Cassader M, et al. A novel approach to control hyperglycemia in type 2 diabetes: sodium glucose co-transport (SGLT) inhibitors: systematic review and meta-analysis of randomized trials. Ann Med. 2012;44:375–393.
   PubMed Web of Science ®Google Scholar
• Hayashi T, Fukui T, Nakanishi N, et al. Dapagliflozin decreases small dense low-density lipoprotein-cholesterol and increases high-density lipoprotein 2-cholesterol in patients with type 2 diabetes: comparison with sitagliptin. Cardiovasc Diabetol. 2017;16:8.
   PubMed Web of Science ®Google Scholar
• Cha SA, Park YM, Yun JS, et al. A comparison of effects of DPP-4 inhibitor and SGLT2 inhibitor on lipid profile in patients with type 2 diabetes. Lipids Health Dis. 2017;16:58.
   PubMed Web of Science ®Google Scholar
• Fadini GP, Bonora BM, Zatti G, et al. Effects of the SGLT2 inhibitor dapagliflozin on HDL cholesterol, particle size, and cholesterol efflux capacity in patients with type 2 diabetes: a randomized placebo-controlled trial. Cardiovasc Diabetol. 2017;16:42.
   PubMed Web of Science ®Google Scholar
• Briand F, Mayoux E, Brousseau E, et al. Empagliflozin, via switching metabolism toward lipid utilization, moderately increases LDL cholesterol levels through reduced LDL catabolism. Diabetes. 2016;65:2032–2038.
   PubMed Web of Science ®Google Scholar
• Filippatos TD, Elisaf MS. Are lower levels of LDL-cholesterol really better? Looking at the results of IMPROVE-IT: opinions of three experts - III. Hellenic J Cardiol. 2015;56:7–9.
   PubMed Web of Science ®Google Scholar
• Catapano AL, Graham I, De Backer G, et al. 2016 ESC/EAS guidelines for the management of dyslipidaemias. Eur Heart J. 2016;37:2999–3058.
   PubMed Web of Science ®Google Scholar
• Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377:644–657.
   PubMed Web of Science ®Google Scholar
• Nadkarni GN, Ferrandino R, Chang A, et al. Acute kidney injury in patients on SGLT2 inhibitors: a propensity-matched analysis. 2017.
   Google Scholar
• Perico N, Ruggenenti P, Remuzzi G. ACE and SGLT2 inhibitors: the future for non-diabetic and diabetic proteinuric renal disease. Curr Opin Pharmacol. 2017;33:34–40.
   PubMed Web of Science ®Google Scholar
• Storgaard H, Gluud LL, Bennett C, et al. Benefits and harms of sodium-glucose co-transporter 2 inhibitors in patients with type 2 diabetes: a systematic review and meta-analysis. PLoS One. 2016;11:e0166125.
   PubMed Web of Science ®Google Scholar
• Leiter LA, Forst T, Polidori D, et al. Effect of canagliflozin on liver function tests in patients with type 2 diabetes. Diabetes Metab. 2016;42:25–32.
   PubMed Web of Science ®Google Scholar
• Yabe D, Nishikino R, Kaneko M, et al. Short-term impacts of sodium/glucose co-transporter 2 inhibitors in Japanese clinical practice: considerations for their appropriate use to avoid serious adverse events. Expert Opin Drug Saf. 2015;14:795–800.
   PubMed Web of Science ®Google Scholar
• Sano M, Takei M, Shiraishi Y, et al. Increased hematocrit during sodium-glucose cotransporter 2 inhibitor therapy indicates recovery of tubulointerstitial function in diabetic kidneys. J Clin Med Res. 2016;8:844–847.
   PubMedGoogle Scholar
• Imprialos KP, Boutari C, Stavropoulos K, et al. Stroke paradox with SGLT-2 inhibitors: a play of chance or a viscosity-mediated reality? J Neurol Neurosurg Psychiatry. 2017;88:249–253.
   PubMed Web of Science ®Google Scholar
• Stavropoulos K, Imprialos KP, Bouloukou S, et al. Hematocrit and stroke: a forgotten and neglected link? Semin Thromb Hemost. 2017;43:591–598.
   PubMed Web of Science ®Google Scholar
• Sonesson C, Johansson PA, Johnsson E, et al. Cardiovascular effects of dapagliflozin in patients with type 2 diabetes and different risk categories: a meta-analysis. Cardiovasc Diabetol. 2016;15:37.
   PubMed Web of Science ®Google Scholar
• Zinman B, Inzucchi SE, Lachin JM, et al. Empagliflozin and cerebrovascular events in patients with type 2 diabetes mellitus at high cardiovascular risk. Stroke. 2017;48:1218–1225.
   PubMed Web of Science ®Google Scholar
• Piepoli MF, Hoes AW, Agewall S, et al. 2016 European guidelines on cardiovascular disease prevention in clinical practice: the Sixth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of 10 societies and by invited experts)developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J. 2016;37:2315–2381.
   PubMed Web of Science ®Google Scholar